Overview
Safety information for CJC-1295 with DAC depends on how extensively it has been studied in humans, how it is manufactured, and in what context it is used. Many catalog peptides have more preclinical than clinical safety data.
Common safety themes
For peptides in general, discussions of side effects often include:
- Local reactions at injection sites.
- Systemic symptoms such as headache, fatigue, or gastrointestinal upset.
- Uncertainties related to long-term exposure, interactions, and product quality.
Context and caveats
Absence of large, well-controlled human studies means that true risk profiles for many peptides remain incompletely defined. Regulatory status, manufacturing controls, and supervision by qualified clinicians are central to interpreting any safety conversation about CJC-1295 with DAC.
Sport & Anti-Doping Warning
CJC-1295 (a GHRH analogue) has been documented in team-sport doping programs, often paired with GHRP-type secretagogues to boost growth hormone and IGF-1.
- >Cronulla-Sutherland Sharks supplements saga (CJC-1295 and GHRP-6 in NRL)
- >Overview of growth hormone–related peptides on the WADA Prohibited List
Long-acting GH-axis peptides like CJC-1295 are prohibited for WADA-code athletes and have featured in multi-player doping investigations in professional rugby league.